183 related articles for article (PubMed ID: 29846165)
1. Risk factors of relapse following glucocorticoid tapering in IgG4-related disease.
Sasaki T; Akiyama M; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):186-189. PubMed ID: 29846165
[TBL] [Abstract][Full Text] [Related]
2. Predictors of disease relapse in IgG4-related disease following rituximab.
Wallace ZS; Mattoo H; Mahajan VS; Kulikova M; Lu L; Deshpande V; Choi HK; Pillai S; Stone JH
Rheumatology (Oxford); 2016 Jun; 55(6):1000-8. PubMed ID: 26888853
[TBL] [Abstract][Full Text] [Related]
3. Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India.
Gupta N; Mathew J; Mohan H; Chowdhury SD; Kurien RT; Christopher DJ; Thangakunam B; Alexander M; Sivadasan A; Tamilarasi V; Valson AT; Gowri M; Kabeerdoss J; Danda D
Rheumatol Int; 2018 Feb; 38(2):203-209. PubMed ID: 28550399
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
[TBL] [Abstract][Full Text] [Related]
5. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial.
Wu Q; Chang J; Chen H; Chen Y; Yang H; Fei Y; Zhang P; Zeng X; Zhang F; Zhang W
Int J Rheum Dis; 2017 May; 20(5):639-646. PubMed ID: 28556584
[TBL] [Abstract][Full Text] [Related]
6. IgG4-related disease: features and treatment response in a multi-ethnic cohort in Singapore.
Fong W; Liew I; Tan D; Lim KH; Low A; Leung YY
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):89-93. PubMed ID: 29846168
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for IgG4-related disease: a prospective, open-label trial.
Carruthers MN; Topazian MD; Khosroshahi A; Witzig TE; Wallace ZS; Hart PA; Deshpande V; Smyrk TC; Chari S; Stone JH
Ann Rheum Dis; 2015 Jun; 74(6):1171-7. PubMed ID: 25667206
[TBL] [Abstract][Full Text] [Related]
10. The Geoepidemiology and Clinical Aspects of IgG4-Related Disease.
Uchida K; Tanaka T; Gershwin ME; Okazaki K
Semin Liver Dis; 2016 Aug; 36(3):187-99. PubMed ID: 27466790
[TBL] [Abstract][Full Text] [Related]
11. IgG4-related disease: a complex under-diagnosed clinical entity.
Yadlapati S; Verheyen E; Efthimiou P
Rheumatol Int; 2018 Feb; 38(2):169-177. PubMed ID: 28681251
[TBL] [Abstract][Full Text] [Related]
12. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
[TBL] [Abstract][Full Text] [Related]
13. Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment.
Yamamoto M; Nojima M; Takahashi H; Yokoyama Y; Ishigami K; Yajima H; Shimizu Y; Tabeya T; Matsui M; Suzuki C; Naishiro Y; Takano K; Himi T; Imai K; Shinomura Y
Rheumatology (Oxford); 2015 Jan; 54(1):45-9. PubMed ID: 24907151
[TBL] [Abstract][Full Text] [Related]
14. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
Wang L; Zhang P; Wang M; Feng R; Lai Y; Peng L; Fei Y; Zhang X; Zhao Y; Zeng X; Zhang F; Zhang W
Arthritis Res Ther; 2018 Apr; 20(1):65. PubMed ID: 29636109
[TBL] [Abstract][Full Text] [Related]
15. Relative Rise of Serum IgG4 Levels After Steroid Therapy for Autoimmune Pancreatitis Predicts the Likelihood of Relapse.
Suzuki D; Shimizu K; Tokushige K
Pancreas; 2018 Apr; 47(4):412-417. PubMed ID: 29517627
[TBL] [Abstract][Full Text] [Related]
16. Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease.
Phaopraphat K; Ngamjanyaporn P; Narongroeknawin P; Kasitanon N; Katchamart W
Int J Rheum Dis; 2020 Nov; 23(11):1468-1473. PubMed ID: 32808722
[TBL] [Abstract][Full Text] [Related]
17. [New strategies for the treatment of IgG4-related disease].
Yamamoto M
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(6):485-490. PubMed ID: 28049956
[TBL] [Abstract][Full Text] [Related]
18. Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort.
Culver EL; Sadler R; Simpson D; Cargill T; Makuch M; Bateman AC; Ellis AJ; Collier J; Chapman RW; Klenerman P; Barnes E; Ferry B
Am J Gastroenterol; 2016 May; 111(5):733-43. PubMed ID: 27091321
[TBL] [Abstract][Full Text] [Related]
19. Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis.
Lu H; Peng L; Zhu L; Feng R; Zhou J; Liu Z; Li J; Luo X; Peng Y; Qin C; Fei Y; Zhao Y; Zeng X; Lai Y; Zhang W
Clin Rheumatol; 2022 Jun; 41(6):1709-1718. PubMed ID: 35175447
[TBL] [Abstract][Full Text] [Related]
20. IgG4-related retroperitoneal fibrosis: a newly characterized disease.
Lian L; Wang C; Tian JL
Int J Rheum Dis; 2016 Nov; 19(11):1049-1055. PubMed ID: 27125330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
